Connect with us

World

Personal Injury Lawyer Richard Console Helping Those Impacted By Popular Diabetes Drug Metformin

mm

Published

on

Doctors have prescribed Metformin to more than 120 million patients worldwide to manage diabetes and other health conditions. Although the FDA has only approved Metformin for the treatment of type-2 diabetes, the drug is widely used off-label to treat many other conditions — including prediabetes, gestational diabetes, polycystic ovary syndrome (PCOS), fertility problems and more.

In June 2020, a recall of the drug was announced by drugmaker Apotex, after finding certain batches containing possible high levels of NDMA, a known animal carcinogen which is also believed to cause cancer in humans. Due to Metformin often being prescribed for off-label use, this means that even a greater number of patients have suffered harm from it. 

Metformin Recall

In May 2020, the FDA identified five pharmaceutical companies that produced batches of Metformin that, according to the agency’s laboratory tests, contained unacceptably high levels of NDMA. The contaminated lots of Metformin that have been recalled are only the extended-release tablets.

As of early June 2020, four of the five pharmaceutical companies that produced contaminated batches of Metformin have initiated recalls of 28 products:

  1. Apotex, which recalled all lots of its metformin products with the NDC (National Drug Code) identification number 60505-0260-1
  2. Actavis Generics (part of Teva Pharmaceuticals), which recalled 14 items with various NDC and lot numbers
  3. Amneal Pharmaceuticals, which recalled all lots of 12 metformin products with various NDC numbers
  4. Time-Cap Labs, Inc. (part of Marksans Pharma), which recalled just 1 lot of metformin (lot number XP9004)

Metformin, NDMA and Cancer

While NDMA is dangerous and a known animal carcinogen and probable human carcinogen, it is fairly common and can be found in everything from air, soil, water and consumer products like cured meat, tobacco and shampoo, according to Everyday Health. Because exposure to very small amounts of NDMA is unavoidable, the FDA set a maximum “reasonably safe” daily intake of 96 nanograms, the equivalent to one billionth of a gram.

Consuming more than the maximum daily amount could raise your risk for cancer. The FDA released a public statement advising the public, “Although there are no reports of NDMA causing cancer in humans, it is reasonable to expect that exposure to NDMA by eating, drinking or breathing could cause cancer in humans.”

According to online pharmacy Valisure, who conducted independent laboratory testing of Metformin, several of the affected batches of the drug contained more than ten times that amount. The batches that performed the worst testing for NDMA had 16 times the recommended amount.

“Imagine ingesting 16 times what’s recommended as the maximum exposure — on top of whatever environmental or dietary exposures you might have —every single day, for years, decades, or even a lifetime,” stated personal injury attorney, Richard Console

The cancer-causing impact of NDMA is believed to be cumulative. “It’s easy to see how a patient exposed to the carcinogen through their diabetes medication could continue to unknowingly stack their cancer risk higher as the year’s pass,” empathizes Console.

Over the years, a myriad of laboratory research on animals and human observation studies those who have been exposed to NDMA. Findings have shown that the chemical can cause or contribute to developing several different forms of cancers. Possible overexposure to the powerful carcinogen has been linked to more than a dozen types of cancer, including the following:

  • Prostate Cancer
  • Lower Esophageal Cancer
  • Non-Hodgkin’s Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Colon Cancer
  • Stomach Cancer
  • Intestinal Cancer
  • Pancreatic Cancer

What You Should Do

First, call your doctor if you have recently been taking Metformin or if you were prescribed it in the past. Do not stop taking the drug without first speaking to a medical professional, as it could cause side effects. The sooner you reach out to your physician to discuss your risks and options, the better.

Once you have spoken to your doctor, contact an attorney. Because cancer often presents itself without an obvious origin, determining whether it’s likely that NDMA caused you to develop cancer, it may be best to reach out to a Metformin injury lawsuit attorney right away. When working to determine a substantial case, they will explore questions like:

  • How long and at what dosage have you been taking Metformin?
  • When were you diagnosed with cancer?
  • In general, is the type of cancer you developed common or rare? What about for patients in your age group, specifically?
  • What risk factors did you already have for cancer you developed?
  • What stage was or is your cancer? Has it seemed to progress more quickly than expected?
  • Has a doctor suggested there may be a link between the medication you took and your cancer? What might a medical expert think?

Additionally, for those that used Metformin prior to developing cancer and developed a rare cancer for which they didn’t have risk factors, there’s a strong chance that NDMA from diabetes medication could be to blame. Those who believe they may have developed cancer after taking Metformin may be eligible for a mass tort claim, which may make getting the compensation you deserve easier.

“When you are taking a medication that is supposed to help you, it’s hard to accept that it could have caused more harm than good,” says Console. “A lawsuit cannot give you back what you have lost, but personal injury attorneys are there to be your advocate and get the justice and compensation to minimize the overwhelming financial burden of a cancer battle.”

Richard P. Console, Jr. is the founder of Console and Associates, PC. He opened his law firm to serve one vital purpose: to help the victims of accidents and injuries at the time when they need help the most. Mr. Console is licensed to practice law in Pennsylvania, New Jersey, and New York. Since 1994, he has represented over 7,000 clients and has achieved a record of success getting clients every dollar of compensation they deserve.

If you or anyone you know has developed cancer following regular use of Metformin, please speak with a Metformin lawsuit attorney right away.

Jenny is one of the oldest contributors of Bigtime Daily with a unique perspective of the world events. She aims to empower the readers with delivery of apt factual analysis of various news pieces from around the World.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

World

TRG Chairman Khaishgi and CEO Aslam implicated in $150 million fraud

mm

Published

on

In a scathing 52-page decision, the Sindh High Court has found that TRG Pakistan’s management was acting fraudulently and that Bermuda-based Greentree Holdings historic and prospective purchase of TRG shares were illegal, fraudulent and oppressive. 

The Sindh High Court has further directed TRGP to immediately hold board elections that have been overdue and illegally withheld by the existing board since January 14, 2025. 

In the landmark ruling, the Sindh High Court has blocked the attempted takeover of TRG Pakistan Limited by Greentree Holdings, declaring that the shares acquired by Greentree, nearly 30% of TRG’s stock, were unlawfully financed using TRG’s funds in violation of Section 86(2) of the Companies Act 2017.

“Having concluded that the affairs of TRGP are being conducted in an unlawful and fraudulent manner and in a manner oppressive to members such as the Petitioner (Zia Chishti), the case falls for corrective orders under sub-section (2) of section 286 of the Companies Act,” Justice Adnan Iqbal Chaudhry concluded.

The case was brought by TRGP former CEO and founder Pakistani-American technology entrepreneur Zia Chishti against TRG Pakistan, its associate TRG International and TRG International’s wholly-owned shell company Greentree Limited.  In addition, the case named AKD Securities for managing Greentree’s illegal tender offer as well as various regulators requiring that they act to perform their regulatory duties.

The case centred around the dispute that shell company Greentree Limited was fraudulently using TRG Pakistan’s own funds to purchase TRG Pakistan’s shares in order to give control to Zia Chishti’s former partners Mohammed Khaishgi, Hasnain Aslam and Pinebridge Investments.

According to the case facts, the Chairman of TRG Pakistan Mohammed Khaishgi and the CEO of TRG Pakistan Hasnain Aslam masterminded the $150 million fraud. They did so together with Hong Kong based fund manager Pinebridge who has two nominees on TRG Pakistan’s board, Mr. John Leone and Mr. Patrick McGinnis.

According to the court papers, Khaishgi, Aslam, Leone, and McGinnis set up a shell company called Greentree which they secretly controlled and from which they started buying up shares of TRG Pakistan.  The fraud was that Greentree was using TRG Pakistan’s funds itself.  The idea was to give Khaishgi, Aslam, Leone, and McGinnis control over TRG Pakistan even though they owned less than 1% of the company, lawyers of the petitioner told the court. 

This was all part of a broader battle for control over TRG Pakistan that is raging between Khaishgi, Aslam, Leone, and McGinnis on one side and TRG Pakistan founder Zia Chishti on the other side.  Zia Chishti has been trying to retake control of TRG Pakistan after he was forced to resign in 2021 based on sexual misconduct allegations made by a former employee of his.  This year those allegations were shown to be without basis in litigation that Chishti launched in the United Kingdom against The Telegraph newspaper which had printed the allegations.  The Telegraph was forced to apologize for 13 separate articles it published about Chishti and paid him damages and legal costs.

After Chishti resigned in 2021, Khaishgi, Aslam, Leone, and McGinnis moved to take total control over TRG Pakistan and its various subsidiaries including TRG International and to block out Chishti.  The Sindh High Court’s ruling today has reversed that effort, ruling the scheme fraudulent, illegal, and oppressive.  

It now appears that Zia Chishti will take control of TRG Pakistan in short order when elections are called.  He and his family are now the largest shareholders with over 30% interest.  He is closely followed by companies related to Jahangir Siddiqui & Company which have over a 20% interest.  The result appears to be a complete vindication for Zia Chishti and damning for his rivals Aslam, Khaishgi, Leone, and McGinnis who have been ruled to have been conducting a fraud.  

TRG Pakistan’s share price declined by over 8% on the news on heavy volume.  Market experts say that this was because the tender offer at Rs 75 was gone and that now shares would trade closer to their natural value.  Presently the shares are trading at Rs 59 per share.

According to the court ruling, since 2021, shell company Greentree had purchased approximately 30% of TRG shares using $80 million of TRG’s own money, which means that that the directors of TRG Pakistan allowed company assets to be funneled through offshore affiliates TRG International and Greentree for acquiring TRG’s shares – a move deemed both fraudulent and oppressive to minority shareholders.  The Sindh High Court also found illegal Greentree’s further attempt to purchase another 35% of TRG shares using another $70 million of TRG’s money in a tender offer. 

The ruling is a major victory for the tech entrepreneur Zia Chishti against his former partners and the legal ruling paves the way for him to take control of TRG in a few weeks.

Continue Reading

Trending